Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Christian AmmitzbøllLars Erik BartelsJakob Bøgh AndersenSigne Risbøl VilsClara Elbaek MistegårdAnders Dahl JohannsenMarie-Louise From HermansenMarianne Kragh ThomsenChristian ErikstrupEllen Margrethe HaugeAnne TroldborgPublished in: ACR open rheumatology (2021)
Antibody measurements against SARS-CoV-2 in patients with RA and SLE after two doses of the BNT162b2 vaccine demonstrated that 23% of patients could not mount a detectable serological response to the vaccine. B cell-depleting therapy (BCDT) is of specific concern, and our findings call for particular attention to the patients receiving BCDT.
Keyphrases
- rheumatoid arthritis
- sars cov
- coronavirus disease
- disease activity
- end stage renal disease
- systemic lupus erythematosus
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- respiratory syndrome coronavirus
- prognostic factors
- ankylosing spondylitis
- interstitial lung disease
- mesenchymal stem cells
- patient reported
- replacement therapy